GLP-1 Therapy for Glycemic Control
Understanding GLP-1 Therapy
Glucagon-like peptide-1 (GLP-1) agonists have emerged as a groundbreaking class of medications for managing type 2 diabetes and associated metabolic disorders. These agents not only improve glycemic control by increasing insulin secretion and suppressing glucagon production, but also lead to weight loss, which varies with the individual drug. The dual GIP and GLP-1 receptor agonist tirzepatide, for instance, has shown greater glycemic and weight-reducing efficacy compared with either class of agent alone.Glycemic Control and Weight Loss Efficacy
1. **Reducing A1C**: GLP-1-based therapies reduce A1C by approximately 1 to 2 percentage points. 2. **Weight Loss**: GLP-1 medications result in weight loss, with the dual GIP and GLP-1 receptor agonist tirzepatide leading to the most significant improvements. 3. **Combination Therapy**: Combination therapy with an GLP-1 receptor agonist or a dual GIP and GLP-1 receptor agonist has been shown to have greater efficacy and durability of glycemic treatment effects, as well as weight and hypoglycemia benefits, than treatment intensification with insulin alone.Benefits Beyond Glycemic Control
